Our Mission

To assist biotech and pharma companies in producing new biologics and vaccines faster, cheaper, more effectively and safer.

History

Our company builds on more than twelve years of experience in performing and optimizing in vitro MHC/epitope binding assays for MHC I and MHC II.

Co-founder and Immunitrack CSO, Sune Justesen, was in charge of developing one of the largest in vitro assay platforms for measuring peptide binding to MHC ever developed. The platform was used to perform a total of 200,000 Kd measurements on 150 MHC alleles. The data was then used to develop the allele-specific predictor NetMHC allele-specific prediction software, still widely used in immune system analysis.

Since its founding in 2013, Immunitrack has developed its unique NeoScreen™ platform, providing researchers with a better tool for assessing the immunogenicity of epitopes.

The Problem

The development of new vaccines or biologics is a lengthy and hugely expensive process that has a relatively high failure rate, despite use of the best resources available. One of the keys to success or failure of a new biotherapeutic lies in how the immune system of the patient reacts to the drug. The “right” immune-stimulating properties are required. Immune surveillance can cause an antidrug immune response that neutralizes the effect and even threatens patient safety. Drug developers need therapeutics that mobilize the immune system to fight the disease, while simultaneously avoid causing an anti-drug immune response that would neutralize the drug’s effect, e.g. by development of neutralizing antibodies (NAb).

Central to all of these issues are the Major Histocompatibility Complex class I and class II (MHCI and MHCII). MHC’s are receptors playing a decisive role in the specificity of the adaptive immune system. These receptors will bind peptides derived from vaccine or biologics and present them to immune cells to prime the immune system to either fight the cancer or degrade the biologic.

Immunitrack’s Solution

At Immunitrack, we provide tools that help the developers of biotherapeutics to predict the impact of a new drug on patient’s immune system, before entering clinical trials. We provide drug developers with tools to select or redesign drug candidates at the early stage of R&D and also to provide reagents to monitor lead drug candidates effect on patient’s immune system.
Immunitrack has unique capabilities to address the central problems surrounding the immune system and new drugs:

1. Unique MHC-peptide binding assays to increase accuracy of personal cancer vaccines.

2. High throughput production of customized MHC/ peptide complexes applicable for mapping patient’s immune response and develop new diagnostics for autoimmune diseases. [Link]

3. Mapping and editing of potential immunogenic epitopes on enzyme or therapeutic antibodies, for decreasing the risks of developing therapeutic specifc NAb.

Immunitrack provides drug developers with tools to select or redesign drug candidates at the early stage of R&D and to provide reagents to monitor lead drug candidates effect on patient’s immune system.